• Media type: E-Article
  • Title: Using a standardised protocol was effective in reducing hospitalisation and treatment use in children with newly diagnosed immune thrombocytopenia
  • Contributor: Labrosse, R; Vincent, M; Nguyen, U‐P; Chartrand, C; Di Liddo, L; Pastore, Y
  • imprint: Wiley, 2017
  • Published in: Acta Paediatrica
  • Language: English
  • DOI: 10.1111/apa.13859
  • ISSN: 0803-5253; 1651-2227
  • Keywords: General Medicine ; Pediatrics, Perinatology and Child Health
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>Childhood immune thrombocytopenia (<jats:styled-content style="fixed-case">ITP</jats:styled-content>) has been associated with low bleeding rates and a high frequency of spontaneous remission. Although current guidelines suggest that most patients are just observed, children still receive platelet‐enhancing therapies for fear of bleeding complications. We hypothesised that a standardised protocol with a step‐down approach would reduce hospitalisation and treatment use.</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>A retrospective chart review was performed on patients diagnosed with acute <jats:styled-content style="fixed-case">ITP</jats:styled-content> between January 2010 and December 2014, before (n = 54) and after (n = 37) the standardised protocol, which was introduced in January 2013. Management and events during the first 3 months following diagnosis were recorded.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The protocol resulted in a 34% decrease in the hospitalisation rate (p &lt; 0.001) at diagnosis. Prednisone treatment duration at diagnosis was also significantly reduced (13.1 versus 5.8 days, p = 0.004). Children over 3 years of age were 3.8 times less likely to be hospitalised (95% <jats:styled-content style="fixed-case">CI</jats:styled-content> 1.94–7.61) and 2.3 times less likely to receive treatment (95% <jats:styled-content style="fixed-case">CI</jats:styled-content> 1.2–4.3). There was no difference in the rate of persistent <jats:styled-content style="fixed-case">ITP</jats:styled-content> (38% versus 30%, p = 0.43) or serious bleeding complications (7% versus 5%, p = 0.70).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Our <jats:styled-content style="fixed-case">ITP</jats:styled-content> management protocol significantly reduced hospitalisation rates and length of prednisone treatment without any increase in disease complications.</jats:p></jats:sec>